Grand Pharma Strategically Controls Duoputai Pharmaceutical Technology, Strengthening the Strategic Plan in Field of Cerebro-cardiovascular Disease Treatment
January 26, 2024
Source: drugdu
47
Xi’an Beilin Pharmaceutical Co., Ltd. (西安碑林药业股份有限公司, Xi’an Beilin), a subsidiary of Grand Pharmaceutical Group Limited (Grand Pharma, 0512.HK), recently entered into the second acquisition agreement with Chongqing Duoputai Pharmaceutical Co., Ltd. (重庆多普泰制药股份有限公司). Xi’an Beilin is to acquire 63% equity interest in Chongqing Duoputai Pharmaceutical Technology Co., Ltd. (重庆多普泰医药科技有限公司, Duoputai Pharmaceutical Technology) at a consideration of RMB442.26 million following the fulfillment of the relevant conditions.
With the completion of the acquisition agreement, Xi’an Beilin will hold a 90% equity interest in Duoputai Pharmaceutical Technology, which will become a subsidiary of Grand Pharma to further consolidate the Group’s market position in the field of cerebro-cardiovascular disease treatment.
https://www.grandpharm.com/en/news/grand-pharma-strategically-controls-duoputai-pharmaceutical-technology-strengthening-the-strategic-plan-in-field-of-cerebro-cardiovascular-disease-treatment
Copyright©2024 Ddu. All rights reserved.
Read more on
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells May 17, 2024
- New DNA Origami Technique to Advance Disease Diagnosis May 17, 2024
- Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck May 17, 2024
- FDA Approves Roche’s HPV Self-Collection Solution, Allowing Patients to Gather Their Own Samples in a Healthcare Setting May 17, 2024
- US study reveals interferon combinations cause lupus symptoms and affect treatment May 17, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
